Edward P. Feener - Jan 7, 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Scientific Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Jan 7, 2022
Transactions value $
$434,832
Form type
4
Date filed
1/11/2022, 03:42 PM
Previous filing
Nov 3, 2021
Next filing
May 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise $239K +33.8K +1512.98% $7.07 36K Jan 7, 2022 Direct
transaction KALV Common Stock Options Exercise $196K +23.9K +66.21% $8.21 59.9K Jan 7, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (right to buy) Options Exercise $0 -33.8K -100% $0.00* 0 Jan 7, 2022 Common Stock 33.8K $7.07 Direct F1
transaction KALV Employee Stock Option (right to buy) Options Exercise $0 -23.9K -46.06% $0.00 27.9K Jan 7, 2022 Common Stock 23.9K $8.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested.
F2 The option vests over a 4 year period: 1/48th on July 4, 2018, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.